Cargando…

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas

SIMPLE SUMMARY: Currently, as a neoadjuvant conversion therapy (NCT), pazopanib combined with neoadjuvant chemoradiotherapy could improve the pathological response of unresectable soft tissue sarcoma (uSTS). However, there is no available evidence of its effectiveness with respect to tumor reduction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Zuoyao, Lu, Yajie, Li, Minghui, Fu, Zhanli, Akbar, Yunus, Li, Jing, Chen, Guojing, Zhang, Hong-Mei, Wang, Qi, Xiang, Liangbi, Wang, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913396/ https://www.ncbi.nlm.nih.gov/pubmed/36765658 http://dx.doi.org/10.3390/cancers15030700

Ejemplares similares

Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients
por: Wang, Bing, et al.
Publicado: (2016)

Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy
por: Kusaba, Hitoshi, et al.
Publicado: (2016)

Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma
por: Li, Minghui, et al.
Publicado: (2019)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
por: Li, Shenglong
Publicado: (2021)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline
por: Verma, S., et al.
Publicado: (2007)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Novel 3D-printed prosthetic composite for reconstruction of massive bone defects in lower extremities after malignant tumor resection()
por: Lu, Yajie, et al.
Publicado: (2019)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma
por: Martin-Liberal, Juan, et al.
Publicado: (2013)

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
por: Verboom, Michiel C., et al.
Publicado: (2019)

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
por: Zhang, Ren‐Shu, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study
por: Wu, Jianhui, et al.
Publicado: (2023)

Outcome and Toxicity of an Ifosfamide-Based Soft Tissue Sarcoma Treatment Protocol in Children. The Importance of Local Therapy
por: Yule, S. Murray, et al.
Publicado: (1998)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma
por: Chhibar, Purva, et al.
Publicado: (2016)

Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns
por: Cai, Meng, et al.
Publicado: (2022)

Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule
por: Almeida, G. F. G., et al.
Publicado: (2011)

Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
por: Saito, Shiro, et al.
Publicado: (2020)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

A Sarcoma at the Site of Previous Extravasation of Adriamycin
por: Ceulemans, Joris, et al.
Publicado: (2002)

Evaluation of Dose-Intense Ifosfamide, with and Without Edatrexate, in Adults with Sarcoma
por: Casper, Ephraim S., et al.
Publicado: (1999)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis
por: Eckert, Franziska, et al.
Publicado: (2010)

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma
por: Imai, Reiko, et al.
Publicado: (2018)

High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
por: Palmerini, Emanuela, et al.
Publicado: (2020)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features
por: Miao, Lei, et al.
Publicado: (2022)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis
por: Carter, Thomas J., et al.
Publicado: (2020)

Combination of ifosfamide and etoposide as a salvage regimen for previously treated soft tissue sarcomas: a retrospective single centre study
por: Ribeiro, Luiz Fernando, et al.
Publicado: (2022)

Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report
por: Cheung, Michelle CM, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h2gfk7jla74onums1i4i2ehg4a